Enhanced antibacterial efficacy against antibiotic-resistant bacteria via nitric oxide-releasing ampicillin polymer substrates.

Animals Mice Anti-Bacterial Agents / pharmacology Nitric Oxide / chemistry Polymers / pharmacology Staphylococcus aureus S-Nitroso-N-Acetylpenicillamine / pharmacology Ampicillin / pharmacology
Ampicillin Antibacterial surface Antibiotics Nitric oxide S-nitroso-N-acetylpenicillamine

Journal

Journal of colloid and interface science
ISSN: 1095-7103
Titre abrégé: J Colloid Interface Sci
Pays: United States
ID NLM: 0043125

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 14 08 2023
revised: 05 09 2023
accepted: 30 09 2023
pmc-release: 01 01 2025
medline: 26 10 2023
pubmed: 14 10 2023
entrez: 13 10 2023
Statut: ppublish

Résumé

The emergence of antibiotic-resistant bacteria poses a pressing threat to global health and is a leading cause of healthcare-related morbidity and mortality. Herein, we report the fabrication of medical-grade polymers incorporated with a dual-action S-nitroso-N-acetylpenicillamine-functionalized ampicillin (SNAPicillin) conjugated molecule through a solvent evaporation process. The resulting SNAPicillin-incorporated polymer materials act as broad-spectrum antibacterial surfaces that improve the administration efficacy of conventional antibiotics through the targeted release of both nitric oxide and ampicillin. The polymer surfaces were characterized by scanning electron microscopy and static contact angle measurements. The nitric oxide (NO) release profile and diffusion of SNAPicillin from polymers were quantified using a chemiluminescence-based nitric oxide analyzer (NOA) and ultraviolet-visible (UV-vis) spectroscopy. As a result, the films had up to 2.96 × 10

Identifiants

DOI: 10.1016/j.jcis.2023.09.188 PMID: 37832467 PMC: PMC10593200
pubmed: 37832467
pii: S0021-9797(23)01902-1
doi: 10.1016/j.jcis.2023.09.188
pmc: PMC10593200
mid: NIHMS1938070
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Nitric Oxide 31C4KY9ESH
Polymers 0
S-Nitroso-N-Acetylpenicillamine 79032-48-7
Ampicillin 7C782967RD

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1763-1774

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL134899
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL151473
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Antimicrob Agents Chemother. 2000 Jul;44(7):1818-24
pubmed: 10858336
Curr Pharm Des. 2015;21(1):31-42
pubmed: 25189865
J Appl Microbiol. 2016 Apr;120(4):1085-99
pubmed: 26784529
ACS Appl Mater Interfaces. 2021 Nov 10;13(44):52425-52434
pubmed: 34723458
J Gen Microbiol. 1989 May;135(5):1291-303
pubmed: 2516117
Curr Med Chem. 2016;23(24):2579-2601
pubmed: 27480214
Compos B Eng. 2017 Jul 15;121:23-33
pubmed: 28989300
Biomater Sci. 2017 Jun 27;5(7):1246-1255
pubmed: 28466898
Chem Rev. 2002 Apr;102(4):1091-134
pubmed: 11942788
J Phys Chem Lett. 2014 Feb 20;5(4):686-8
pubmed: 26270837
J Bacteriol. 2009 Dec;191(23):7333-42
pubmed: 19801410
ACS Appl Mater Interfaces. 2023 Mar 29;15(12):15185-15194
pubmed: 36926823
APMIS. 2017 Apr;125(4):365-375
pubmed: 28407421
J Control Release. 2015 Nov 10;217:228-34
pubmed: 26374942
ACS Appl Mater Interfaces. 2019 Sep 25;11(38):34652-34662
pubmed: 31483604
Biomaterials. 2013 Sep;34(28):6957-66
pubmed: 23777908
ACS Appl Mater Interfaces. 2021 Dec 8;13(48):56931-56943
pubmed: 34818503
Antimicrob Agents Chemother. 1993 Dec;37(12):2522-6
pubmed: 8109913
J Am Chem Soc. 2004 Feb 11;126(5):1348-9
pubmed: 14759186
BMC Microbiol. 2014 Sep 02;14:234
pubmed: 25179448
Front Microbiol. 2016 Aug 17;7:1260
pubmed: 27582732
Chem Soc Rev. 2012 May 21;41(10):3742-52
pubmed: 22362384
Virulence. 2012 May 1;3(3):271-9
pubmed: 22546899
J Infect Dis. 1994 Sep;170(3):720-3
pubmed: 7915751
ACS Appl Mater Interfaces. 2021 Sep 22;13(37):43892-43903
pubmed: 34516076
J Biomed Mater Res A. 2023 Apr;111(4):451-464
pubmed: 36594584
Pharmacol Ther. 1997 Aug;75(2):111-34
pubmed: 9428001
Infect Drug Resist. 2018 Nov 15;11:2321-2333
pubmed: 30532565
Appl Environ Microbiol. 2006 Mar;72(3):2005-13
pubmed: 16517649
Sci Technol Adv Mater. 2011 Sep 23;12(5):055007
pubmed: 27877445
Rev Inst Med Trop Sao Paulo. 2014 Jul-Aug;56(4):341-6
pubmed: 25076436
ACS Appl Mater Interfaces. 2021 May 5;13(17):19613-19624
pubmed: 33904311
Langmuir. 2011 Dec 6;27(23):14160-8
pubmed: 22023013
Biomater Sci. 2023 Sep 26;11(19):6561-6572
pubmed: 37594048
Int J Polym Mater. 2016;65(15):769-778
pubmed: 27493297
Front Microbiol. 2019 May 03;10:913
pubmed: 31130925
ACS Appl Mater Interfaces. 2015 Oct 14;7(40):22218-27
pubmed: 26393943
Ann Surg. 1995 Mar;221(3):220-35
pubmed: 7717775
Int J Antimicrob Agents. 2018 Mar;51(3):299-303
pubmed: 28887201
Infect Drug Resist. 2014 Jun 20;7:167-76
pubmed: 25018641
Shock. 2016 Dec;46(6):597-608
pubmed: 27454373
FEMS Immunol Med Microbiol. 2012 Jul;65(2):183-95
pubmed: 22444301
J Antibiot (Tokyo). 2016 Dec;69(12):871-878
pubmed: 27189119
Acta Pharmacol Sin. 2005 Mar;26(3):259-64
pubmed: 15715920
ACS Biomater Sci Eng. 2016 Sep 12;2(9):1483-1492
pubmed: 27660819
Future Microbiol. 2014;9(8):987-1007
pubmed: 25302955
J Am Chem Soc. 2001 Oct 3;123(39):9712-3
pubmed: 11572708
Biomater Sci. 2013 Nov 1;1(11):
pubmed: 24288588
Photochem Photobiol. 1994 Apr;59(4):463-7
pubmed: 8022889
Sci Rep. 2017 Oct 19;7(1):13623
pubmed: 29051609

Auteurs

Yi Wu (Y)

School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA 30602, United States.

Mark R Garren (MR)

School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA 30602, United States.

Lori M Estes Bright (LM)

School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA 30602, United States.

Patrick Maffe (P)

School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA 30602, United States.

Megan Brooks (M)

School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA 30602, United States.

Elizabeth J Brisbois (EJ)

School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA 30602, United States. Electronic address: ejbrisbois@uga.edu.

Hitesh Handa (H)

School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA 30602, United States; Pharmaceutical and Biomedical Science Department, College of Pharmacy, University of Georgia, Athens, GA 30602, United States. Electronic address: hhanda@uga.edu.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Enhanced antibacterial efficacy against...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Enhanced antibacterial efficacy against...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Enhanced antibacterial efficacy against...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Oxydes › Oxydes d'azote › Monoxyde d'azote › Enhanced antibacterial efficacy against...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Enhanced antibacterial efficacy against...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Enhanced antibacterial efficacy against...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés soufrés › Pénicillamine › N-Acétyl-S-nitroso-pénicillamine › Enhanced antibacterial efficacy against...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Pénicillines › Benzylpénicilline › Ampicilline › Enhanced antibacterial efficacy against...